UNSPSC 51351912: Ulipristal acetate

This classification denotes an anti-progestin with the molecular formula C30H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF7V70N02B. European Medicines Agency schedules ulipristal acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30470. The term ulipristal acetate is a United States Adopted Name designation. As of Q4 2014, ULIPRISTAL ACETATE remains the US FDA Preferred Term for this commodity. Ulipristal acetate bears US NLM identifiers UMLS ID C2723461 and NCI Concept Code C91057.

SMILES: CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)OC(=O)C.

UNSPSC 51351912 Ulipristal acetate is a Commodity code identifying a specific pharmaceutical active ingredient used in emergency contraceptive formulations. State and local governments procure ulipristal acetate primarily through public health departments, correctional facilities, and family planning clinics to stock emergency contraceptive medications for eligible populations. The drug is dispensed as a single-dose oral tablet taken within 72 hours of unprotected intercourse and is often part of broader reproductive health and family planning service offerings. Procurement typically flows through state Medicaid programs, public health supply contracts, and correctional health services. Issuing bodies include state departments of health, county health departments, municipal public health agencies, and corrections departments operating custody facilities. A small number of special-purpose health districts and regional family planning authorities also source the medication through state or local channels.

The code shows minimal recent solicitation activity in state and local procurement records. No representative opportunities are currently documented in publicly posted RFPs, RFQs, IBFs, or ITBs under this commodity code across major state and local jurisdictions. Procurement of ulipristal acetate at the state and local level tends to occur through standing Medicaid pharmaceutical contracts, group purchasing organization frameworks, or direct purchase orders to licensed pharmaceutical distributors rather than through competitive open solicitations. Interested vendors should monitor state Medicaid procurement offices and public health department supply contracts, particularly in states with expanded family planning service mandates, for indirect sourcing opportunities.